In Bloomberg Law, Attorneys Discuss Navigating a Resilient but Uncertain Venture Capital Fundraising Environment

In The News
December 14, 2022

Despite the 2022 sharp downturn in the public markets, the private biotech ecosystem has proved to be remarkably resilient. Nevertheless, venture-backed biotech companies face difficult decisions when it comes to fundraising.

In a Bloomberg Law article, co-head of the firm's life sciences and health care industry group and the venture capital & emerging companies practice Marc Rubenstein and venture capital & emerging companies associate Rajarshi Banerjee explain that companies that think strategically about the timing and terms of their next fundraise and thoughtfully explore alternatives to equity financings will emerge from this current period of uncertainty poised to take advantage of improved market conditions.